Octavio Espinoza
Chief Financial OfficerMr. Octavio Espinoza, also known as Tavo, is Chief Financial Officer of Ligand Pharmaceuticals Incorporated from November 2022. Mr. Espinoza has been with Ligand since 2016 serving in a variety of finance leadership roles at Ligand, most recently as Senior Vice President, Finance from 2019 to 2022 and senior Director of Accounting from 2016 to 2019. Prior to joining Ligand, Mr. Espinoza served as Senior Director, Finance for Receptos, a publicly traded drug-discovery company, that was acquired by Celgene (now Bristol-Myers Squibb). Before Receptos, Mr. Espinoza was Senior Director, Accounting for Illumina, a publicly traded life sciences analytics and genetics sequencing tools company and prior to Illumina, served as Senior Manager, Accounting at Intuit. Mr. Espinoza began his professional career in public accounting at PricewaterhouseCoopers and holds a B.S. in business administration from San Diego State University and a license as a Certified Public Accountant in the State of California. He is Director of XOMA Royalty Corporation from July 14, 2026.
Positions
- Company NameLigand Pharmaceuticals IncorporatedStock CodeLGNDPositionChief Financial OfficerColleagues
- TCTodd C. DavisCEO & Director
- JWJohn Warren KozarichIndependent Chairman
- ATAndrew T. ReardonChief Legal Officer & Secretary
- PJPaul J. HaddenSenior Vice President of Investments & Business Development
- MJMelanie J. HermanExecutive Director of Investor Relations and Financial Planning & Analysis
- JMJason M. AryehIndependent Director
- SLStephen Lawrence SabbaIndependent Director
- JHJason HaasIndependent Director
